论文部分内容阅读
目的 :通过随机对照研究 ,比较 NP与 MVP方案治疗晚期非小细胞肺癌 (NSCL C)的疗效 ,并观察其毒副作用。方法 :共 6 5例晚期 NSCL C患者随机入组 ,治疗组 30例应用 NP方案 (NVB+DDP) ,对照组 35例应用 MVP方案 (MMC+VDS+DDP)。每病例至少化疗 2疗程。疗效及毒副作用评价均按 WHO标准进行。结果 :治疗组 CR3例 ,PR11例 ,总有效率 46 .6 % ,对照组 CR1例 ,PR12例 ,总有效率 37.1%。治疗组总有效率要高于对照组 ,但无统计学差异 (P>0 .0 5 )。治疗组中位生存期 8.5月 ,而对照组 7.6月 ,两组无差异 (P>0 .0 5 )。两组病例主要的毒副作用是骨髓抑制、消化道反应及静脉炎。结论 :NP方案可以在 NSCL C治疗中作为一线方案逐步应用 ,并进一步研究
Objective : To compare the efficacy of NP and MVP regimens in the treatment of advanced non-small cell lung cancer (NSCL C) by randomized controlled trials and to observe their toxic and side effects. METHODS: A total of 65 patients with advanced NSCL C were randomized. 30 patients in the treatment group received NP regimen (NVB+DDP), and 35 patients in the control group received MVP regimen (MMC+VDS+DDP). At least 2 courses of chemotherapy per case. The efficacy and toxic and side effects were evaluated according to WHO standards. Results: There were 3 cases of CR in the treatment group and 11 cases of PR. The total effective rate was 46.6%, CR1 cases in the control group, and PR12 cases. The total effective rate was 37.1%. The total effective rate of the treatment group was higher than that of the control group, but there was no statistical difference (P>0.05). The median survival time was 8.5 months in the treatment group and 7.6 months in the control group (P>0.05). The main toxic side effects in both groups were myelosuppression, gastrointestinal reactions and phlebitis. Conclusion: The NP regimen can be gradually applied as a first-line regimen in NSCL C treatment, and further study